Study on cefodizime, a new cephem antibiotic, in the field of pediatrics
Sato, H.; Narita, A.; Matsumoto, K.; Nakazawa, S.; Suzuki, H.; Nakanishi, Y.; Niino, K.; Nakazawa, S.
Japanese Journal of Antibiotics 42(6): 1306-1321
1989
ISSN/ISBN: 0368-2781 PMID: 2795855 Document Number: 334757
Experimental and clinical study of cefodizime (CDZM, THR-221), a newly developed cephem antibiotic, was done in the field of pediatrics and the results obtained are summarized as follows: 1. Serum levels and urine excretion were examined after 60-minute drip infusion of CDZM at a dose level of 10 mg/kg to 1 patient, at 20 mg/kg to 4 and at 40 mg/kg to 1. Peak levels in serum were 66.3 .mu.g/ml for the 10 mg/kg dose occurring 1 hours after the dose, 118.1 .mu.g/ml (mean) for 20 mg/kg, 259.2 .mu.g/ml for 40 mg/kg, thus a dose-response was observed. T 1/2's (beta phase) were between 1.17 and 1.69 hours. Urinary recovery rates of the drug were between 71.5% and 98.0% in the first 8 hours after administration. 2. The concentration in the cerebrospinal fluid was 0.76 .mu.g/ml and the serum level was 380.67 .mu.g/ml at 15 minutes after intravenous administration of 433 mg of CDZM to a patient with purulent meningitis. 3. The clinical efficacy rate was 95.2% in a total of 21 cases, i.e., 1 purulent meningitis. 10 respiratory tract infection, 3 whooping cough, 5 urinary tract infection, 1 purulent infection of soft tissues and 1 acute thyroiditis. Diarrhea occurred in 1 case as adverse reactions. Abnormal changes in laboratory test results occurred as 1 case each of slightly elevated GOT.cntdot.GPT and GOT.